# The Impact of Rosiglitazone on Regression of Atherosclerosis

> **NCT00166803** · NA · SUSPENDED · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes Mellitus, Atherosclerosis

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00166803
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2005-06
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** no fund
- **Last updated:** 2009-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00166803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00166803, "The Impact of Rosiglitazone on Regression of Atherosclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00166803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*